Istituto Clinico Humanitas, IRCCS, Via Manzoni 113, Rozzano, Milan, Italy.
Vascul Pharmacol. 2011 Oct;55(4):106-10. doi: 10.1016/j.vph.2011.08.216. Epub 2011 Aug 16.
Cardiometabolic diseases (CMD) (such as atherosclerosis, diabetes, and hypertension) are the primary cause of death and disability in the Western world. Although lifestyle programs and therapeutic approaches have significantly reduced the socio-economic burden of CMD, a large number of events still cannot be avoided (the so called residual risk). Recent developments in genetics and genomics provide a platform for investigating further this area with the aim of deepening our understanding of the atherosclerotic phenomena underlying CMD, for instance by providing better information on the type of subjects who would benefit the most from therapeutic interventions, or by discovering new genetic and metabolic derangements that may be targeted for the development of new interventions. MicroRNAs (miRNA) are short, non-coding RNAs that negatively regulate the expression of proteins by binding to specific sequences on the 3' region of target mRNAs. Bioinformatics analysis predicts that each miRNA may regulate hundreds of targets, suggesting that miRNAs may play roles in almost every biological pathway and process, including those of the cardiovascular system. Studies are beginning to unravel their fundamental importance in vessel biology. Here, we review recent advance regarding the involvement of miRNAs in arterial remodeling and atherosclerosis.
心血管代谢疾病(CMD)(如动脉粥样硬化、糖尿病和高血压)是西方世界主要的死亡和残疾原因。尽管生活方式计划和治疗方法显著降低了 CMD 的社会经济负担,但仍有大量事件无法避免(所谓的残余风险)。遗传学和基因组学的最新发展为进一步研究这一领域提供了一个平台,目的是加深我们对 CMD 相关动脉粥样硬化现象的理解,例如,提供更多关于最受益于治疗干预的受试者类型的信息,或者发现可能针对新干预措施的新遗传和代谢紊乱。MicroRNAs(miRNA)是短的非编码 RNA,通过与靶 mRNAs 3' 区域的特定序列结合来负调控蛋白质的表达。生物信息学分析预测每个 miRNA 可能调节数百个靶标,这表明 miRNA 可能在几乎所有的生物学途径和过程中发挥作用,包括心血管系统。研究开始揭示它们在血管生物学中的基本重要性。在这里,我们回顾了 miRNA 参与动脉重塑和动脉粥样硬化的最新进展。